Mandate

Vinge advises Hansa Medical in connection with a directed share issue

November 15, 2018 Capital Markets and Public M&A

The board of directors of Hansa Medical has resolved on a directed new issue of shares, whereby Hansa Medical will raise proceeds of approximately SEK 453 / USD 50 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Cowen, RBC Capital Markets and Skandinaviska Enskilda Banken.

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The company’s lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications.

Vinge’s team has consisted of Dain Hård Nevonen, Erik Sjöman, Joakim Hagberg and Edin Agic. 
 

Related

Vinge has advised Triton in connection with sale of shares in Ambea AB (publ)

In total, 8.4 million shares were placed at a price of SEK 43.50 per share, corresponding to a total value of approximately SEK 365 million.
November 29, 2023

Vinge represents Lassie AB in a capital raising of SEK 260 million

Vinge has advised the pet insurance broker Lassie AB in connection with a capital raising of SEK 260 million in order to continue the expansion of the business.
November 29, 2023

Vinge advises Expedition Growth Capital in connection with its investment in Factbird 

Expedition Growth Capital, together with the Export and Investment Fund of Denmark (EIFO), have completed its investment in the Danish tech company Factbird. Vinge acted for Expedition Growth Capital in connection with the investment.
November 27, 2023